Compare Phillips 66 (PSX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs TG Therapeutics Inc — how do they compare? Phillips 66 trades at $261.27 (market cap $103.40B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Phillips 66 is far larger — about 12.1× TG Therapeutics Inc's market cap, and Phillips 66 pays a 1.96% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PSX | TGTX | |
|---|---|---|
Market Cap | $103.40B | $8.53B |
Sector | Energy | Health |
52-Week High | $260.78 | $59.06 |
52-Week Low | $126.76 | $26.94 |
Enterprise Value | $119.87B | $8.74B |
Dividend Yield | 1.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $259.14, up 1.59% today and near its 52-week high, supported by bullish technical signals and strong earnings beats in recent quarters. The stock shows robust profitability with a 24.02% ROE and attractive valuation metrics, including a P/E of 14.79. Recent news highlights momentum from high gas prices and refining efficiency gains, with a dividend of $1.27 payable in September 2026.
Outlook remains positive due to earnings momentum and sector tailwinds, but risks include volatile energy markets and declining revenue trends. Analysts are predominantly bullish with a $242.45 consensus target, though the current price exceeds this, suggesting near-term caution. Institutional buying and stable cash flow growth support long-term potential.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
